BROSSARD, Quebec, March 13, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:
ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE
platform based on Artificial Intelligence (AI), announces today the signing of a significant renewal
contract in the United Arab Emirates consisting of a turnkey one-year screening contract for 2 CARA platform services.
So far, DIAGNOS’ healthcare services have been rendered in 16 countries worldwide. During the period covered by
the agreement, DIAGNOS estimates that an additional 5,000 patients will be screened in UAE using its CARA platform.
“We are excited to continue our collaboration with one of the largest pharmaceutical companies in the world.
More and more, we, DIAGNOS and our strategic pharmaceutical partner, are educating governments around the world to our Wellness
Program (CARA) and demonstrating the benefits and tremendous cost savings that can be attained from it. We also continue to
implement our growth strategy with this key pharmaceutical partner,” said André Larente, President of DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of
its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that
integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image
enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the
internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for
commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking
compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
This news release contains forward-looking information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
